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ABSTRACT
Introduction The aim of this study is to develop practical 
and affordable models to (a) diagnose people with diabetes 
and prediabetes and (b) identify those at risk of diabetes 
complications so that these models can be applied to the 
population in low- income and middle- income countries 
(LMIC) where laboratory tests are unaffordable.
Methods and analysis This statistical and economic 
modelling study will be done on at least 48 000 
prospectively recruited participants aged 40 years or 
above through community screening across 20 predefined 
regions in India. Each participant will be tested for 
capillary random blood glucose (RBG) and complete a 
detailed health- related questionnaire. People with known 
diabetes and all participants with predefined levels of RBG 
will undergo further tests, including point- of- care (POC) 
glycated haemoglobin (HbA1c), POC lipid profile and POC 
urine test for microalbuminuria, retinal photography using 
non- mydriatic hand- held retinal camera, visual acuity 
assessment in both eyes and complete quality of life 
questionnaires. The primary aim of the study is to develop 
a model and assess its diagnostic performance to predict 
HbA1c diagnosed diabetes from simple tests that can be 
applied in resource- limited settings; secondary outcomes 
include RBG cut- off for definition of prediabetes, diagnostic 
accuracy of cost- effective risk stratification models for 
diabetic retinopathy and models for identifying those at 
risk of complications of diabetes. Diagnostic accuracy 
inter- tests agreement, statistical and economic modelling 
will be performed, accounting for clustering effects.
Ethics and dissemination The Indian Council of 
Medical Research/Health Ministry Screening Committee 
(HMSC/2018–0494 dated 17 December 2018 and 
institutional ethics committees of all the participating 
institutions approved the study. Results will be published 
in peer- reviewed journals and will be presented at national 
and international conferences.
Trial registration number ISRCTN57962668 V1.0 
24/09/2018.
INTRODUCTION
Background
Diabetes and its complications are common 
causes of morbidity and mortality globally. 
Low- income and middle- income countries 
(LMIC) are most affected by the diabetes 
epidemic, where significant number of 
people with undiagnosed diabetes present 
with complications of diabetes.1 More than 
30% of world population is estimated to have 
prediabetes.2 The most common risk factors 
for diabetes and its complications are long- 
term diabetes, uncontrolled hyperglycaemia, 
hypertension and dyslipidaemia. As high as 
90% of people with type 2 diabetes are dyslip-
idaemic and 60%–85% are hypertensive. In 
addition, 90% of people with type 2 diabetes 
are obese.3 There is an unmet need to screen 
for prediabetes and diabetes in LMIC, where 
primary healthcare is underdeveloped and 
laboratory tests are costly.
Strengths and limitations of the study
 ► This is the first national prospective study that will 
assess the prevalence of sight- threatening diabetic 
retinopathy (DR) in various regions in India.
 ► The study will provide evidence on the accuracy of 
point- of- care glycated haemoglobin as a screening 
tool for diabetes.
 ► The study will provide several diagnostic models on 
diabetes and its complications.
 ► Validation of the models may not be possible in all 
cases.
 ► The treatment pathway for patients identified with 
sight- threatening DR or other complications of dia-
betes is according to local protocols.
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Screening for people at risk of diabetes
According to the WHO, diabetes is confirmed by labora-
tory tests in a symptomatic individual if glycated haemo-
globin (HbA1c) is ≥48 mmol/L (≥6.5%) or fasting blood 
glucose is ≥7 mmol/L (≥126 mg/dL), or a random blood 
glucose (RBG) is ≥11.1 mmol/L (≥200 mg/dL) or after a 
2- hour oral glucose tolerance test, blood glucose is ≥11.1 
mmol/L (≥200 mg/dL). In asymptomatic individuals, 
diabetes has to be confirmed by two of these laboratory 
tests.4 Standard laboratory- based HbA1c test has the 
added advantage of providing an average estimation of 
the glycaemic status of an individual over the previous 3 
months and is helpful in categorising people into normal 
(HbA1c <42 mmol/mol; <6.0%), prediabetes (HbA1c 
42–47 mmol/mol; 6%–6.4%) and diabetes (HbA1c is ≥48 
mmol/mol; ≥6.5%).4 The lower limit of HbA1c in predia-
betes may be as low as 5.7%.5
However, none of these tests are practical for population- 
level screening in LMIC where non- technical personnel 
often conduct screening for diabetes in non- clinical envi-
ronments. HbA1c also cannot be measured in patients 
with haemoglobinopathies. A number of LMIC have 
high prevalence of malaria and various haemoglobinop-
athies, including thalassaemia and sickle cell anaemia. 
Therefore, there is an unmet need to use simple tests to 
identify people at risk for diabetes. Despite its variability, 
capillary RBG is the the most common blood test done 
in such situations.6 Prediabetes is not clearly defined by 
RBG despite several studies that have attempted to define 
cut- off values of RBG against HbA1c.6–15 More conve-
nient point- of- care (POC) HbA1c kits are now available 
that show good correlation with laboratory- based HbA1c 
estimation.16 It is, therefore, appropriate to validate POC 
HbA1c against RBG in community screening. Although 
there are several studies that have evaluated various 
screening tests for prediabetes, these studies have used 
laboratory- based HbA1c measurements or fasting blood 
glucose as the index test.17 In contrast, this study will 
focus on POC HbA1c as the index test for prediabetes to 
inform community screening. Studies using POC HbA1c 
as a reference test have included specific disease cohorts 
only, or had a small sample size within hospital settings or 
conducted post- hoc analysis on previously recruited study 
cohorts and most importantly, did not compare the accu-
racy of these tests with known non- laboratory (NL) based 
diabetes risk scores.6–15
Due to the large numbers of undiagnosed diabetes, it 
is also useful to investigate whether it is more efficient to 
triage people at risk of diabetes in the population using 
non- invasive diabetes risk scores, such as Madras Diabetes 
Research Foundation- Indian Diabetes Risk Score (MDRF- 
IDRS)18 to further reduce the cost of screening with POC 
HbA1c or RBG.
Screening for complications of diabetes mellitus
Approximately 30% of people with diabetes present with 
macrovascular complications such as cardiovascular, cere-
brovascular and peripheral vascular diseases.3 In addition, 
this population may also have microvascular complications, 
including diabetic kidney disease (DKD) in 30%–50%, 
diabetic retinopathy (DR) in 30% and diabetic neurop-
athy in 30%–50%.3 Despite this public health burden, 
people with diabetes are not systematically screened for 
these complications of diabetes in LMIC due to economic 
constraints, paucity of public health programmes, inad-
equately trained manpower and under- resourced infra-
structure. Recently, several cardiovascular risk scores such 
as the NL INTERHEART risk score (IHRS) have been 
successfully used in community screening programmes.19 
It may be possible to develop similar models to identify 
people at risk of sight- threatening DR (STDR) and blind-
ness. Although systematic annual photographic retinal 
screening after pupil dilatation using standard costly 
retinal cameras and prompt treatment of STDR have 
reduced the rate of blindness in the UK,20 these complex 
and costly screening protocols are not translatable to 
LMIC and hence alternative screening methods must 
be considered to ensure population coverage. There 
are recent reports of accuracy of identifying STDR from 
the retinal images obtained by affordable and portable 
non- mydriatic cameras and graded either manually or by 
artificial intelligence.21 22 Therefore, adding retinopathy 
screening, using these hand- held retinal cameras, to mini-
mally invasive tests, such as blood pressure (BP) and urine 
dip test for microalbuminuria and other NL risk scores, 
may be an efficient and cost- effective screening option to 
identify people at risk of diabetes complications.
Objectives
Our study has three important objectives. The first objec-
tive is to determine the ideal tests that could identify 
people at risk of diabetes and prediabetes in community 
screening that can be applied to LMIC. In order to accom-
plish this, we would evaluate the correlation of RBG levels 
with POC HbA1c levels and decide on a cut- off value for 
RBG from HbA1c to diagnose prediabetes. Second, we 
will evaluate whether initial triaging with NL diabetes 
risk score followed by either RBG or POC HbA1c only to 
the identified risk group is more effective than screening 
everyone for diabetes using either RBG or POC HbA1c. 
Third, we will develop affordable, easily deliverable and 
clinically effective model to accurately identify people at 
risk of complications of diabetes in community screening, 
especially DR.
Secondary objectives are aimed at guiding future poli-
cies on screening of diabetes and its complications. As the 
study involves a large sample and the setting up of a teleop-
hthalmology model to screen for DR across 20 regions in 
India, we will be able to report the regional prevalence 
of DR and the associated risk factors, the inter- grader 
reliability and the accuracy of using artificial intelligence 
to grade DR. We will also conduct economic modelling 
and process evaluation of a holistic model for screening 
of all complications of diabetes. If sample size permits, 
we will be able to report on region- specific and diverse 
population- specific rates of diabetes and complications, 
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visual impairment, quality of life and risk models specific 
to regions to inform local health authorities.
METHODS AND ANALYSIS
Study design
This is a statistical and economic modelling study that will 
be done on cross- sectional and prospectively recruited 
participants from community- based screening in order to 
accurately identify people at risk of diabetes, prediabetes 
and complications of diabetes.
Study setting
This community screening will be conducted across 20 
regions in India, each led by a local clinical centre with a 
trained ophthalmologist responsible for the study at that 
site (figure 1). Each region will have three clusters strat-
ified into urban, rural and a predefined special category 
of population such as people with poor access to health-
care, or persons that are presumed to be at high risk or 
low risk of developing diabetes. The study will involve a 
door- to- door survey, with questionnaires and POC tests 
performed by fieldworkers. Each cluster will screen at 
Figure 1 Map of India with 20 centres marked.
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least 800 consenting individuals aged 40 years or above 
for a cumulative sample size of a minimum of 48 000 
participants. If any cluster or centre does not reach their 
target recruitment, it will be made up by another cluster 
or centre with the same stratified population.
Stratified sampling
In each region, we predefined a geographic area as urban 
or rural based on a multistage sampling technique using 
data from the 2011 census of India. A census enumera-
tion block that usually consists of 125–150 households 
with a population of 650–700 is the primary sampling 
unit for urban areas, while villages are defined in the 
rural areas. Bigger villages are further divided to ensure 
that approximately 300 households can be covered. The 
house- to- house survey will be conducted by approaching 
each household in consecutive streets in each area. If the 
household members are not available, a further two visits 
by the fieldworkers are permitted. In each household, 
all available members aged 40 years or above, who meet 
the inclusion criteria, will be invited to participate in the 
study.
The special category groups include two groups: (a) 
people working under high stress leading to poor and 
untimely eating habits (such as policemen, truck and 
taxi drivers, manual labourers, fishermen, factory staff 
and professionals in stressful jobs) and those presumed 
to be at low risks such as certain religious groups and (b) 
people with poor health seeking behaviour and/or under 
social stigma (such as tribal, slum population and people 
with infection like HIV or leprosy). All survey clusters 
and special groups are independent samples. The total 
population for the study is the total recruited participants 
in all the 20 regions, including the special population 
(figure 1).
Selection of participants
The inclusion criteria are adults who are ≥40 years of age 
(special groups may contain adult population of any age), 
who are local residents of Indian origin and are willing 
to give informed consent (see online supplemental 
appendix 1 for sample informed consent form).
Exclusion criteria include vulnerable adults in whom 
it may not be possible to carry out all the tests; pregnant 
and breastfeeding women; anyone in the opinion of the 
fieldworkers deemed too ill to be screened; and those 
who are currently participating in intervention trials with 
investigational medicinal products.
Study procedures
The fieldworkers will be responsible for providing 
adequate information about the study and obtaining 
consent from willing participants. A unique patient iden-
tification number will be allocated for each participant to 
ensure anonymity. A detailed case report form containing 
a structured questionnaire will be answered by all partic-
ipants in the study (see online supplemental appendix 2 
for case report form). The data collected will include age, 
gender, marital status, socioeconomic status (education, 
occupation and average monthly income), MDRF- IDRS 
and IHRS that contain questions on lifestyle (smoking 
and alcohol habits, diet and physical activity and stress),6 7 
brief medical and ocular history with any relevant medi-
cations and/or surgery, and family history of diabetes 
and cardiovascular disease. The structured questionnaire 
will be translated into local languages and administered 
by trained fieldworkers. Questionnaires will be validated 
in 200 subjects in 2 study sites at the start of the study 
and the case report forms and the study database will be 
refined to ensure generalisability and reproducibility.
Anthropometric measurements will be performed using 
the same kits supplied to all sites, and local fieldworkers 
will be trained on regular calibration of the kits. Height (in 
cm) will be measured using a stadiometer (SECA Model 
214, Seca Gmbh Co, Hamburg, Germany). Weight (in kg) 
will be measured with an electronic weighing scale (SECA 
Model 807, Seca Gmbh Co, Hamburg, Germany) kept 
on a firm horizontal flat surface. Body mass index will be 
auto- calculated. Waist circumference will be measured at 
the smallest horizontal girth between the costal margins 
and the iliac crest at the end of expiration using a non- 
stretchable measuring tape. Hip measurement will be 
done with the arms relaxed at the sides, at the maximum 
circumference over the buttocks.
BP will be recorded in sitting position in the right arm 
to the nearest 1 mm Hg using the electronic OMRON 
machine (Omron Corporation, Kyoto, Japan). Partic-
ipants with BP ≥140/90 mm Hg and not on antihyper-
tensive drugs will be advised to contact a physician for 
further evaluation. A simple finger- prick test will be used 
to assess capillary RBG using a standard POC testing 
device (OneTouch Verio Glucometer, LifeScan Inc, 
USA). All participants with known diabetes or those with 
capillary RBG ≥160 mg/dL and 50 participants with RBG 
110–159 mg/dL in each cluster will receive further tests. 
These include HbA1c estimation using a POC kit (A1c 
Now Plus, PTS Diagnostics, USA) and POC lipid estima-
tion (Cardiochek PA analyser, PTS Diagnostics, USA). A 
POC urine sample (Chemstrip Micral dipstick, Roche 
Diagnostics, Mannheim) will be tested for the presence 
or absence of microalbuminuria.
Visual acuity in both eyes will be recorded using a 
tablet/smartphone- based vision check web- based appli-
cation (Peek Vision). Non- mydriatic fundus photog-
raphy of both eyes will be done using a handheld retinal 
camera (Visuscout 100, Zeiss, Germany). This portable 
and battery- operated camera with in- built Wi- Fi facilities 
will allow capture of colour and red- free retinal images 
covering 40° field of view through pupils as small as 3.5 
mm. Two fundus images (one macula- centred and one 
disc- centred) of each eye will be captured. In case of 
any media opacities making fundus imaging difficult, 
the anterior segment image of each eye would be taken. 
A teleophthalmology system will be set up whereby the 
images captured by each fieldworker will be uploaded 
to a cloud- based study specific database and graded at 
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the local clinical centre by an ophthalmologist/optom-
etrist (primary grader), as well as transferred to four 
central reading centres, where grading will be done by 
a second ophthalmologist (secondary grader). Discrep-
ancies between primary and secondary grading will 
result in arbitration by a senior retinal consultant. Any 
participants with STDR, ungradable images and other 
incidental findings requiring further evaluation will be 
informed by the fieldworkers and counselled to attend 
hospital eyecare service. DR will be classified as per the 
International Clinical Disease Severity Scale for DR as 
no DR, mild/moderate/severe non- proliferative DR 
(NPDR) and proliferative DR (PDR).23 Diabetic macular 
oedema (DMO) will be determined as present or absent. 
STDR would be defined as the presence of severe NPDR, 
PDR and/or DMO. Artificial intelligence may be applied 
to grade these images and if found to be as accurate as 
human graders, it will be incorporated to the screening 
model.
The well- established and widely used quality of life 
questionnaire EQ- 5D (Euro Quality of life) will also be 
administered with additional vision ‘bolt- on’ questions 
and vision- related quality of life.24–26 The study flow is 
shown in figure 2. In addition, centre administrators at 
each clinical site will be responsible for contacting, by 
letter or phone, and tracking follow- up of those partic-
ipants who need further referral to an eye hospital for 
treatment for STDR or due to ungradable retinal images.
Quality assurance
Training of research personnel on study assessments 
will be done at study initiation meetings, where the core 
study team, laboratory staff and camera manufacturers 
will certify individual fieldworkers. In addition, the data 
manager in the UK will provide on- site training at each 
centre, as well as continuous remote training throughout 
the study. The ophthalmologists or their representatives 
at each clinical centre will be responsible for training 
their team who may not meet the pre- set criteria or any 
new member joining the team. A monitoring plan will be 
in place to ensure that regular remote monitoring is done 
throughout the study period.
Quality control
Calibration procedure and frequency for the weighing 
machine, BP apparatus, POC kits for capillary RBG and 
HbA1c and urine will be followed at all centres to avoid 
any bias or errors. All personnel involved in the grading 
of retinal images must have completed a study- specific 
training course.
Data management
The data will be entered directly by the fieldworkers into 
a tablet that is linked to a cloud- based electronic database 
hosted in India. In situations where internet access is not 
available, paper case report forms will be used at the site 
and later transcribed into the database. The data in the 
database will be monitored by the study monitoring team. 
The retinal photographs will also be uploaded to the plat-
form. The WHO STEPwise approach to surveillance will 
be used to develop the cloud- based electronic database.27 
The study is monitored by an independent committee 
and the progress of the study is reviewed by the grant 
executive committee.
Database functionality and quality assurance
The study electronic database (Playon, Bangalore, India) 
will be hosted on a dedicated secure server in India. All 
data will be managed through this system. The database 
will be programmed to perform validation checks, such as 
range checks to prevent data entry errors, missing data to 
be flagged up to ensure completion of the data entry. The 
system will provide for data security and also have formal 
database lock functionality and it will support real time 
data cleaning and reporting.
Statistical considerations
The statistical methods will be developed fully within 
a statistical analysis plan, to be finalised before data-
base lock. Diagnostic accuracy publications will follow 
recognised Standards for Reporting Diagnostic accuracy 
studies guidelines and the observational component will 
follow the Strengthening the Reporting of Observational 
Studies in Epidemiology guidelines. Table 1 shows the 
reference and index tests for diagnostic accuracy aspect 
of the study.
Accuracy will be measured by sensitivity and speci-
ficity of tests to detect diabetes, prediabetes and people 
at risk of complications of diabetes. Clustering will be 
used to accommodate any over dispersion. Consistency 
of these statistics will be explored across centres and clus-
ters (urban, rural and special population). Area under 
receiver operating characteristic (ROC) curve will be 
used to compare models representing the overall perfor-
mance of tests under comparison. Refinement of test 
components (eg, combinations of tests or questionnaire 
items) will be developed, and internally validated where 
sufficient data are available. The number of false posi-
tives will be identified directly from the data. From the 
estimates of sensitivity and the specificity of diabetes risk 
score to detect prediabetic (or diabetic) and its estimated 
prevalence, it will be possible to estimate the false positive 
rate and the complement of the positive predictive value. 
All estimates will be accompanied by estimated 95% CIs, 
which account for both clustering and stratification.
For the modelling framework, a marginal model with a 
logit link will be used, with retinal photograph determi-
nation of the reference outcome. Model- predicted prob-
abilities will enable the area under the ROC curve to be 
estimated with 95% CI allowing for clustering, and accom-
panied by estimates of sensitivity, specificity, predictive 
values and likelihood ratios. Diabetes alone, and diabetes 
or prediabetes will be explored, as will already- identified 
and newly identified diabetes. For research questions 
on the diabetes diagnostic model, the denominator will 
principally be all those diagnosed with diabetes, whether 
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already diagnosed or newly diagnosed. Interaction with 
this term (known vs newly diagnosed) will contribute 
to the analysis involving costs. Further modelling will 
explore use of the data from those that were found not to 
have diabetes or prediabetes.
Marginal logistic modelling will be used to identify the 
tests and questionnaire items which are most predictive, 
following a recommended approach.28 Continuous 
predictors will be handled using the fractional polynomial 
approach.29 In the sample size section, it can be seen that 
the dataset is large enough to allow models to assess up 
to 10 (reliably) and 20 (less reliably) dependent on intra-
cluster correlation. Differences in area under the ROC 
curve and differences in specificity for given sensitivity 
Figure 2 Study flow diagram.
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will be estimated. The sample size is large enough to 
assess existing tests and to develop models. There may be 
limited scope to validate models. However, interim anal-
ysis will allow assumed rates and numbers to be assessed; 
the number of cases with STDR will be estimated more 
accurately, and this may enable more sophisticated forms 
of internal validation. Model validation would include 
calibration after model discrimination.30 Clustering 
within estimates of sensitivity, specificity and areas under 
the ROC curves will account for clustering, considering 
use of the non- parametric stratified bootstrap. A similar 
approach will be undertaken for the model to identify 
people at risk of complications of diabetes. Models for DR 
will also test the accuracy of artificial intelligence graded 
images compared with human graders.
Sample size calculation
The sample size is determined by considering the numbers 
of expected STDR, as this analysis will have the smallest 
number of cases with the outcome. With 20 regions, we 
expect 216 cases of STDR. From 48 000 people (2400 per 
centre) screened, of whom about 4800 are expected to 
be known diabetes and, we suspect, another 4800 will be 
newly detected diabetes. As 30% of the former group, 
and 15% of the latter group, are expected to have DR, 
we anticipated 2160 people to have DR, of whom 216 to 
have STDR.
Considering that some patients would come from the 
same family, and some from the same area, we assumed 
that outcomes at the area level would have an allowed intra-
centre correlation (ICC) coefficients of approximately up 
to 0.05 and to 0.10 for new and known diabetes, respec-
tively. At the area level, with approximately 100 cases per 
region, and a working ICC of 0.075, we expect a design 
effect of 8.5. This calculation has been based on conser-
vative allowances and approximations, which allow for 
deviations in the actual intracluster correlation coef-
ficients from those anticipated, or for variation in the 
actual number of cases across centres. This means that 
the effective sample size (were the sample to be free from 
clustering) is 25 STDR cases for covariates, which are 
constant at the region level, or highly correlated among 
families within the same area. Using the rule of 10 people 
per covariate in order to plan the number of possible 
covariates, this implies that it will be possible to include 
10–20 covariates (216/10) at the participant- level depen-
dent on whether there is no, modest or moderately high 
ICC in the covariates, and 1–2 covariates (25/2) either at 
the area/family level for a stable diagnostic STDR model. 
All models will include observations at the participant 
level in order to accommodate participant- level covariates 
and will accommodate clustering further by including 
two area contrast terms; these reflect whether a partici-
pant lives in the strata of regions that are urban, rural or 
a special population. Models will be from the ‘marginal’ 
class so that correlation can be accommodated while 
importantly retaining a participant- specific interpretation 
of resulting estimates. The study will continue to recruit 
to enable process evaluation and other substudies to be 
incorporated.
Health economics analysis plan
The health economics modelling will address the following 
three questions: (1) What is the cost- effectiveness of a 
new screening pathway for diabetes and prediabetes? 
The screening approaches will comprise: diabetes risk 
score followed by definitive laboratory tests; diagnostic 
model which the statistical modelling finds to be more 
accurate than diabetes risk score followed by definitive 
laboratory tests; RBG for all without diabetes risk score 
based prescreen; HbA1c test with no prescreen and; no 
screening; (2) What is the cost effectiveness of a new 
screening pathway for DR among people with diabetes? 
The screening approaches will comprise a new method, 
which the statistical modelling finds to be accurate; 
retinal photographs only and no screening and (3) What 
is the cost effectiveness of a new screening pathway for a 
range of other complications of diabetes among people 
with diabetes? The screening approaches will comprise 
a new method, which the statistical modelling finds to 
be accurate; a combination of HbA1c, lipids and urine 
tests and colour retinal images; and no screening. In each 
case, therefore, one comparator will be a ‘gold standard’ 
(HbA1c test, retinal photographs and combination of 
tests as above) and another will be no screening and no 
treatment until symptoms of DR, DKD or other complica-
tions of diabetes are experienced.
The modelling will draw on the following data sources: 
(1) the data collected through the house- to- house 
Table 1 Reference and Index tests
Community screening for diabetes
Reference standard Index test
1. RBG 1. POC HbA1c
2. Non- invasive diabetes risk 
scores
Community screening for prediabetes
1. POC HbA1c 1. RBG
2. Non- invasive diabetes risk 
scores
Community screening for complications of diabetes
1. Serum lipid profile
 ► TC
 ► Non- HDL cholesterol
 ► LDL cholesterol
 ► HDL cholesterol
 ► TC:HDL ratio
 ► Triglyceride
Risk- based screening tool 
for complications of diabetes 
using minimally or non- 
invasive tests
2. HbA1c or RBG
3. Microalbuminuria
4. Retinal photography for 
retinopathy for all people with 
diabetes
HbA1c, glycated haemoglobin; HDL, high density lipoprotein; LDL, low 
density lipoprotein; POC, point- of- care; RBG, random blood glucose; 
TC, total cholesterol.
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Table 2 SMART India collaborators
Site no. Name of principal investigator Hospital name Ethics approval and date
1 Dr Pramod Bhende
Dr Rajiv Raman
Sankara Nethralaya, 
Chennai, Tamil Nadu
Vision Research Foundation, Institutional Review 
Board
Study code: VRF/674A-2018- P
Date of approval: 22 March 2018
2 Dr Ramachandran Rajalakshmi
Dr Viswanathan Mohan
Dr Mohan’s Diabetes 
Specialities Centre, Chennai, 
Tamil Nadu
Madras Diabetes Research Foundation, Institutional 
Ethics Committee
Date of approval: 6 March 2018
Reference number: MDRF/NCT/02–01/2018
3 Dr Kim Ramasamy Aravind Eye Hospital, 
Madurai, Tamil Nadu
Aravind Medical Research Foundation, Institutional 
Ethics Committee
Reg. number: ECR/182/Inst/TN/2013/RR-19
IRB2018010BAS
Date of approval: 21 April 2018
4 Dr Taraprasad Das
Dr Padmaja K Rani
LV Prasad Eye Institute, 
Hyderabad, Telangana
LV Prasad Eye Institute, Ethics Committee
Reference number: LEC07-18-096
Date of approval:19th July 2018
5 Dr Rupak Roy
Dr Supita Das
Sankara Nethralaya, Kolkata Vision Research Foundation, Institutional Review 
Board
Study code: VRF/674A-2018- P
Date of approval: 22 March 2018
6 Dr Deepa Mohan Dr Mohan’s Diabetes 
Specialities Centre, Mysuru, 
Karnataka
Madras Diabetes Research Foundation, Institutional 
Ethics Committee
Date of approval: 6 March 2018
Reference number: MDRF/NCT/02–01/2018
7 Dr V Narendran
Dr George Manayath
Aravind Eye Hospital, 
Coimbatore, Tamil Nadu
Aravind Medical Research Foundation, Institutional 
Ethics Committee
Number: ECR/182/Inst/TN/2013
IRB2018010BAS
Date of approval: 18 Aug 2018
8 Dr Giridhar Anantharaman
Dr Mahesh Gopalakrishnan
Giridhar Eye Institute, 
Cochin, Kerala
Giridhar Eye Institute, Ethics Committee
IEC protocol no: 36/2018
Date of approval: 13 June 2018
9 Dr Sundaram Natarajan
Dr Radhika Krishnan
Aditya Jyot Hospital, 
Mumbai, Maharashtra
Aditya Jyot Eye Hospital, Ethics Committee
Date of approval: 30 Aug 2018
10 Dr Sheena Liz Mani Dr Tony Fernandez Eye 
Hospital, Aluva, Kerala
Dr Tony Fernandez Eye Hospital, Ethics Committee
Date of approval: 21 June 2018
11 Dr Manisha Agarwal Dr Shroff’s Charity Eye 
Hospital, New Delhi
Dr Shroff’s Charity Eye Hospital, Ethics Committee
Date of approval: 29 January 2018
12 Dr Tapas Padhi
Dr Umesh Behera
LV Prasad Eye Institute, 
Bhubaneshwar, Odisha
LV Prasad Eye Institute, Ethics Committee
Date of approval :10 October 2018
13 Dr Harsha Bhattacharjee
Dr Manabjyoti Barman
Sri Sankaradeva Nethralaya, 
Guwahati, Assam
Sri Sankaradeva Nethralaya, Institutional Ethics 
Committee
Reference number: SSN/IEC/OCTOBER/2018/09
Date of approval: 8 October 2018
14 Dr Gajendra Chawla Vision Academy–The Socio 
Medical Society, Bhopal, 
Madhya Pradesh
Vision Research Foundation, Institution Review 
Committee
Approval number: 674A-2018- P
Date of approval: 22 March 2018
15 Dr Alok Sen Sadguru Netra Chikitsalaya, 
Chitrakoot, Madhya Pradesh
Vision Research Foundation, Institutional Review 
Committee
Approval number: 674A-2018- P
Date of approval: 22 March 2018
16 Dr Moneesh Saxena Aurobindo Nethralaya, 
Raipur, Chhattisgarh
Shri Aurobindo Medical Research Centre, Institutional 
Review Board
Date of approval: 22 June 2018
Continued
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screening and associated retinal images, blood and urine 
tests on the rates of true and false positives and negatives, 
the characteristics of people with diabetes and its compli-
cations, and their quality of life; (2) the data collected 
through the study on the cost per person of this screening 
and its cost per person with diabetes, and the costs of 
clinic visits and treatments for DR; (3) the data and infor-
mation from past studies on the incidence rates by age 
and gender of diabetes, DR and other complications of 
diabetes, transition rates between different stages of the 
disease and disease- specific mortality rates; and (4) the 
data from past studies on the costs of care for people 
with varying severities of DR and other complications of 
diabetes and on their quality of life. For those variables on 
which data cannot be collected in this study or obtained 
from past studies, expert views will be sought, and sensi-
tivity analyses conducted.
The modelling will comprise development of Markov 
models to track people aged 40 years and above (a) 
through incidence of diabetes, any DR, STDR, severe 
visual impairment/blindness and (b) through incidence 
of diabetes, mild complications other than DR and severe 
complications other than DR. For each disease state, the 
models will contain estimates of average annual costs of 
care and average EQ- 5D quality of life. The design of the 
models will be developed in the light of data availability.
The models will be used to estimate lifetime costs and 
quality of life (monetised quality adjusted life years, 
QALYs) from age 40 years and above (a) where the planned 
screening approach (or approaches) is conducted 
and necessary treatment given shortly after screening; 
(b) where the ‘gold standard’ screening approach is 
conducted and necessary treatment given shortly after 
screening; and (c) where no screening is conducted and 
no treatment given until symptoms develop. The incre-
mental cost effectiveness of the screening in compar-
ison with ‘gold standard’ screening will be estimated by 
comparing (a) and (b); and its incremental cost effective-
ness in comparison with no screening will be estimated by 
comparing (a) and (c). A wide range of sensitivity analysis 
will be conducted, and a variety of discount rates may be 
applied.
We will also evaluate and compare the cost effectiveness 
of retinal photography for everyone with diabetes versus 
retinal photography only for people with diabetes with 
suspected high risk of DR, to be developed through the 
statistical modelling. We will develop a health economics 
plan after reviewing available data. As an example, Racha-
pelle et al31 used a WHO- recommended approach for 
a cost- effectiveness threshold in their study of the cost 
utility of telemedicine to screen for DR in India. Under 
that approach, the interventions costing less than per 
capita gross domestic product (GDP) per QALY were 
considered very cost effective, interventions between one 
time and three times GDP were considered cost effective 
and interventions more than three times GDP were not 
considered cost effective.
Process evaluation
A detailed process evaluation plan will be developed to 
evaluate the holistic screening for all complications of 
diabetes, including the teleophthalmology. For each 
quantitative outcome measure, we will systematically 
embed qualitative measures in each RE- AIM (reach, 
efficacy, adoption, implementation and maintenance) 
dimension to evaluate the implementation strategy of 
community screening with minimally invasive tests.32 33
Outcomes
The primary outcome is the correlation of RBG levels and 
POC HbA1c levels. Secondary outcomes include the cut- 
off value of RBG to define prediabetes; diagnostic accu-
racy of risk stratification models for diabetes; prevalence 
and risk stratification for screening for DR; risk model for 
those at risk of complications of diabetes; identification of 
cost- effective diagnostic model for diabetes, prediabetes 
and complications of diabetes and process evaluation of 
minimally invasive community screening for diabetes and 
its complications.
Site no. Name of principal investigator Hospital name Ethics approval and date
17 Dr Asim K Sil
Dr Subhratanu Chakabarty
Netra Niramay Niketan, 
Haldia, West Bengal
Vivekendra Mission Asram Netra Niramay Niketan, 
Institutional Review Board
Date of approval: 4 September 2018
18 Dr Thomas Cherian
Dr Reesha KR
Little Flower Hospital and 
Research Centre, Angamaly, 
Kerala
Little Flower Hospital and Research Centre, Ethics 
Committee
Date of approval:4 June 2018
19 Dr Rushikesh Naigaonkar
Dr Abishek Desai
Ganapathy Nethralaya, 
Jalna, Maharashtra
Shri Ganapati Netralaya, Institutional Ethics 
Committee
Date of approval: 28 July 2018
20 Dr Col Madan Deshpande
Dr Sucheta Kulkarni
HV Desai Hospital, Pune, 
Maharashtra
PBMA’s H V Desai Eye Hospital, Institutional Review 
Committee
Number: HVD/EC/17/2018
Date of approval :21st June 2018
Table 2 Continued
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Patient and public involvement
No patient involved.
Ethics and dissemination
The Indian Council of Medical Research’s Health Ministry 
Screening Committee (HMSC/2018–0494; dated: 17 
December 2018) and the institutional ethical committees 
of all the participating institutions have approved the 
study (table 2). The main ethical issues in relation to this 
study are the identifications of people with risk factors for 
prediabetes, diabetes and its complications. However, the 
benefits of early diagnosis outweigh these risks. Partici-
pants who screen positive for any risk factors will be 
advised about referral to the local hospitals for treatment. 
Any breach of confidentiality will be minimised by anony-
mising participant identifiable information.
The results will be published in open access peer- 
reviewed journals, presented at scientific meetings and 
shared with the funder, and specific communication 
will be organised to target health professionals, policy 
decision- makers, regulatory bodies and commercial 
bodies for development of better predictive devices. The 
anonymised study data will be analysed by the statistical 
team in the UK. Anonymised patient level data access will 
be made available to researchers from appropriate data 
archive for sharing purposes following publication of the 
study.
Author affiliations
1NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, 
London, UK
2Vision Sciences, UCL Institute of Ophthalmology, London, UK
3Retina Department, Vision Research Foundation, Sankara Nethralaya, Chennai, 
India
4Deaprtment of Diabetes, Madras Diabetes Research Foundation, Dr Mohan's 
Diabetes Specialities Centre, Chennai, India
5Retina Department, Hyderabad Eye Research Foundation, LV Prasad Eye Institute, 
Hyderabad, India
6Retina Department, Aravind Medical Research Foundation, Madurai, India
7Nightingale- Saunders Clinical Trials and Epidemiology Unit, King's College London, 
London, UK
8Centre for Health Service Economics and Organisation, University of Oxford, 
Oxford, UK
9Institute for Connected Communities, University of East London, London, UK
10Department of Ophthalmology, National University Hospital, Singapore
11Department of Diabetes, University Hospital, Birmingham, UK
Acknowledgements The authors would like to thank all the SMART India 
collaborators, including fieldworkers, each centre staff, reading centre staff, 
Jitendra Pal Thethi for the study database and the study participants.
Contributors SMART India writing group: SS, RRaman, RRajalakshmi, VM, DM, TD, 
KR, ATP, RW, GN, GL, WH, DC, JR, JS and RRamakrishnan). Conceptualisation: SS, 
RRaman, RRajalakshmi, VM, KR, DM, JR, ATP, GL, TD, GN and RW; methodology: 
SS, TD, GN, RW, ATP, JR, DM and RRamakrishnan; formal analysis: SS, GN, RW, 
ATP and RRamakrishnan; writing and original draft preparation: SS, DC, RRaman, 
RRajalakshmi, TD, GN, RW, JS, WH, JR and ATP; writing, and review and editing: 
SS, RRaman, RRajalakshmi, VM, KR, GL, TD, GN, RW, JR, ATP, WH, DM, DC and 
RRamakrishnan; funding acquisition: SS, RRaman, RRajalakshmi, VM, KR, TD, GN 
and RW. Table 2: on behalf of the SMART India Collaborators.
Funding This work was supported by Global Challenges Research Fund and UK 
Research and Innovation through the Medical Research Council (grant number MR/
P027881/1). This funding source had no role in the design of this study and will not 
have any role during its execution, analyses, interpretation of the data or decision 
to submit results.
Map disclaimer The depiction of boundaries on this map does not imply the 
expression of any opinion whatsoever on the part of BMJ (or any member of its 
group) concerning the legal status of any country, territory, jurisdiction or area or 
of its authorities. This map is provided without any warranty of any kind, either 
express or implied.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Sobha Sivaprasad http:// orcid. org/ 0000- 0001- 8952- 0659
Rajiv Raman http:// orcid. org/ 0000- 0001- 5842- 0233
A Toby Prevost http:// orcid. org/ 0000- 0003- 1723- 0796
REFERENCES
 1 International Diabets Federation. IDF diabetes atlas, 9th edition. 
Brussels: International Diabets Federation, 2019. https://www. 
diabetesatlas. org/ en/
 2 Hostalek U. Global epidemiology of prediabetes - present and future 
perspectives. Clin Diabetes Endocrinol 2019;5:5.
 3 Bar- Tana J. Type 2 diabetes - unmet need, unresolved pathogenesis, 
mTORC1- centric paradigm. Rev Endocr Metab Disord 
2020;21:613–29.
 4 World Health Organisation. Classification of diabetes, 2019. 
Available: www. who. int/ publications- detail/ classification- of- diabetes- 
mellitus
 5 American Diabetes Association. Standards of medical care in 
diabetes. Diabetes Care 2019;42:S1–204.
 6 Somannavar S, Ganesan A, Deepa M, et al. Random capillary blood 
glucose cut points for diabetes and pre- diabetes derived from 
community- based opportunistic screening in India. Diabetes Care 
2009;32:641–3.
 7 Ziemer DC, Kolm P, Foster JK, et al. Random plasma glucose 
in serendipitous screening for glucose intolerance: screening 
for impaired glucose tolerance study 2. J Gen Intern Med 
2008;23:528–35.
 8 Rolka DB, Narayan KM, Thompson TJ, et al. Performance of 
recommended screening tests for undiagnosed diabetes and 
dysglycemia. Diabetes Care 2001;24:1899–903.
 9 Susairaj P, Snehalatha C, Raghavan A, et al. Cut- Off value of random 
blood glucose among Asian Indians for preliminary screening of 
persons with prediabetes and undetected type 2 diabetes defined 
by the glycosylated haemoglobin criteria. J Diabetes Clin Res 
2019;1:53–8.
 10 Tahrani AA, Geen J, Hanna FWF, et al. Predicting dysglycaemia in 
patients under investigation for acute coronary syndrome. QJM 
2011;104:231–6.
 11 Badings EA, Dyal L, Schoterman L, et al. Strategies to detect 
abnormal glucose metabolism in people at high risk of cardiovascular 
disease from the origin (outcome reduction with initial Glargine 
intervention) trial population. J Diabetes 2011;3:232–7.
 12 Ain Q, Latif A, Jaffar SR, et al. Evaluation of random plasma glucose 
for assessment of glycaemic control in type 2 diabetes mellitus. J 
Pak Med Assoc 2017;67:1353–6.
 13 Gill GV, Hardy KJ, Patrick AW, et al. Random blood glucose 
estimation in type 2 diabetes: does it reflect overall glycaemic 
control? Diabet Med 1994;11:705–8.
 on D
ecem
ber 17, 2020 by guest. Protected by copyright.
http://bm
jopen.bm
j.com
/
BM
J O
pen: first published as 10.1136/bm
jopen-2020-039657 on 12 D
ecem
ber 2020. D
ow
nloaded from
 
11Sivaprasad S, et al. BMJ Open 2020;10:e039657. doi:10.1136/bmjopen-2020-039657
Open access
 14 Rasmussen JB, Nordin LS, Rasmussen NS, et al. Random blood 
glucose may be used to assess long- term glycaemic control among 
patients with type 2 diabetes mellitus in a rural African clinical 
setting. Trop Med Int Health 2014;19:1515–9.
 15 Otieno FCF, Ng'ang'a L, Kariuki M. Validity of random blood glucose 
as a predictor of the quality of glycaemic control by glycated 
haemoglobin in out- patient diabetic patients at Kenyatta national 
Hospital. East Afr Med J 2002;79:491–5.
 16 Sicard DA, Taylor JR. Comparison of point- of- care HbA1c test 
versus standardized laboratory testing. Ann Pharmacother 
2005;39:1024–8.
 17 Barry E, Roberts S, Oke J, et al. Efficacy and effectiveness of screen 
and treat policies in prevention of type 2 diabetes: systematic 
review and meta- analysis of screening tests and interventions. BMJ 
2017;356:i6538.
 18 Mohan V, Anbalagan VP. Expanding role of the Madras Diabetes 
Research Foundation - Indian Diabetes Risk Score in clinical 
practice. Indian J Endocrinol Metab 2013;17:31–6.
 19 Joseph P, Yusuf S, Lee SF, et al. Prognostic validation of a non- 
laboratory and a laboratory based cardiovascular disease risk score 
in multiple regions of the world. Heart 2018;104:581–7.
 20 Scanlon PH, Aldington SJ, Leal J, et al. Development of a cost- 
effectiveness model for optimisation of the screening interval 
in diabetic retinopathy screening. Health Technol Assess 
2015;19:1–116.
 21 Natarajan S, Jain A, Krishnan R, et al. Diagnostic accuracy of 
community- based diabetic retinopathy screening with an Offline 
artificial intelligence system on a smartphone. JAMA Ophthalmol 
2019;137:1182–8.
 22 Rajalakshmi R, Arulmalar S, Usha M, et al. Validation of smartphone 
based retinal photography for diabetic retinopathy screening. PLoS 
One 2015;10:e0138285.
 23 Wilkinson CP, Ferris FL, Klein RE, et al. Proposed International 
clinical diabetic retinopathy and diabetic macular edema disease 
severity scales. Ophthalmology 2003;110:1677–82.
 24 Misajon R, Hawthorne G, Richardson J, et al. Vision and quality of 
life: the development of a utility measure. Invest Ophthalmol Vis Sci 
2005;46:4007–15.
 25 Peacock S, Misajon R, Iezzi A, et al. Vision and quality of life: 
development of methods for the VisQoL vision- related utility 
instrument. Ophthalmic Epidemiol 2008;15:218–23.
 26 Janssen MF, Birnie E, Bonsel GJ. Quantification of the level 
descriptors for the standard EQ- 5D three- level system and 
a five- level version according to two methods. Qual Life Res 
2008;17:463–73.
 27 The WHO STEP wise approach to surveillance of noncommunicable 
diseases (STEPS). Noncommunicable diseases and mental health. 
World Health organization. 20 Avenue Appia, 1211 Geneva 27, 
Switzerland, 2014. Available: http://www. who. int/ ncd_ surveillance
 28 Royston P, Moons KGM, Altman DG, et al. Prognosis and prognostic 
research: developing a prognostic model. BMJ 2009;338:b604.
 29 Sauerbrei W, Royston P. Building multivariable prognostic and 
diagnostic models: transformation of the predictors by using 
fractional polynomials. J R Stat Soc Ser A Stat Soc 1999;162:71–94.
 30 Altman DG, Vergouwe Y, Royston P, et al. Prognosis and prognostic 
research: validating a prognostic model. BMJ 2009;338:b605.
 31 Rachapelle S, Legood R, Alavi Y, et al. The cost- utility of telemedicine 
to screen for diabetic retinopathy in India. Ophthalmology 
2013;120:566–73.
 32 Moore GF, Audrey S, Barker M, et al. Process evaluation of 
complex interventions: medical Research Council guidance. BMJ 
2015;350:h1258.
 33 Forman J, Heisler M, Damschroder LJ, et al. Development and 
application of the RE- AIM quest mixed methods framework for 
program evaluation. Prev Med Rep 2017;6:322–8.
 on D
ecem
ber 17, 2020 by guest. Protected by copyright.
http://bm
jopen.bm
j.com
/
BM
J O
pen: first published as 10.1136/bm
jopen-2020-039657 on 12 D
ecem
ber 2020. D
ow
nloaded from
 
   
 
Patient Information Sheet and Consent form V1.0 dated 14-02-2018 1 
INFORMED CONSENT FORM 
FOR PARTICIPATION IN THE SMART INDIA STUDY 
India has the second largest number of people with diabetes in the world and the number is 
increasing every year. It is well known that people with diabetes are at a higher risk of getting eye 
problems, heart attack/ stroke, or kidney disease. Some people may have altered blood sugar 
levels before they actually develop diabetes. This is an All India study which is being done to find 
out the burden of pre-diabetes and diabetes and the complications due to diabetes, especially the 
eye complication of diabetes called retinopathy. For this purpose you will be asked some 
questions which will be recorded in a questionnaire. Blood pressure and a few anthropometric 
measurements will be taken. All people will then have a finger prick blood test done and photo of 
the back of the eye (retina) taken using a simple retinal camera. Some additional blood tests and 
urine test will be done for a subset of people.  It is possible that this study could determine that 
you have diabetes and / or its associated disorders. If so, you will benefit from this information as 
you can seek early treatment for these disorders. The information you provide in the 
questionnaire, results of your blood tests and retinal photography will be kept confidential. 
  
Patient identification number for this 
study   
 
Title of the project SMART INDIA study(Statistical Modelling and Risk 
Assessment of Type 2 diabetes complications in India)  
Name of Principal Investigator (s)  
 
 
The contents of the patient information sheet that has been provided have been read carefully by 
me/explained in detail to me, in a language that I comprehend, and I have fully understood the 
contents. 
I confirm that I have had the opportunity to ask questions. The nature and purpose of the study 
and its potential risks / benefits and expected duration of the study, and other relevant details 
have been explained to me in detail. I understand that my participation in this study is voluntary 
and that I am free to withdraw at any time, without giving any reason. 
I understand that the information collected about me from participation in this study and sections 
of any of the results may be looked at by responsible individuals involved in this research project 
either in India or outside India. Anonymised data and retinal images may be shared with other 
researchers. 
I agree to take part in the above study. 
 
 
 
 
----------------------------------------                                                                                   Date: 
 (Signature/Left Thumb impression of participant) 
Place:    Place
 
 
Name of the Participant:    _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
Son/Daughter/spouse of:    _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
Complete postal address: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
    _ _ _
    _ _ _
1) Witness 
   
--------------------------------------                                                       Date: 
                (Signature)      
 
Name      
                                              
Address: 
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PART 1 – House hold Details- House Survey Record 
1 Centre  
 
2 Region Type 
1 Urban 
2 Rural 
3 Special 
 
 
3 
 
Address  
 
4 Phone / Mobile Number:  
 
5 City  
 
6 Pin  
 
7 Household Status 
1 No one available in this household 
2 Household not willing to participate 
3 Available 
                                                                                  If 1 or 2 skip question No.8 
8 If available, number of people in house above 40 years  
 
    
9 
Enter details of people in the 
 house hold 
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9.1. Person-1 
a 
 
Participation 
1 Willing to take part 
2 Type 1 diabetic - exclusion 
3 Gestational diabetes - exclusion 
4 Other exclusion 
If 4, Reason   
                                                                                  If 3 skip “b”, if 1 or 2 skip “c and d” 
b Gender 
1 Male 
2 Female 
3 Other (do not want to disclose, transgender, etc.) 
  
c Name of the person 1 Example: Ajith Kumar  
 
d Initials of the person 1 Example: AK  
 
9.2 Person-2 
a Participation 
1 Willing to take part 
2 Type 1 diabetic - exclusion 
3 Gestational diabetes - exclusion 
4 Other exclusion 
 If 4, Reason   
                                                                                  If 3 skip “b”, if 1 or 2 skip “c and d” 
b Gender 
1 Male 
2 Female 
3 Other (do not want to disclose, transgender, etc.) 
 
c Name of the person 2  
 
d Initials of the person 2  
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9.3. Person-3 
a Participation 
1 Willing to take part 
2 Type 1 diabetic - exclusion 
3 Gestational diabetes - exclusion 
4 Other exclusion 
 If 4, Reason   
                                                                                  If 3 skip “b”, if 1 or 2 skip “c and d” 
b Gender 
1 Male 
2 Female 
3 Other (do not want to disclose, transgender, etc.) 
                                                                                    
c Name of the person 3  
 
d Initials of the person 3  
 
9.4. Person-4 
a Participation 
1 Willing to take part 
2 Type 1 diabetic - exclusion 
3 Gestational diabetes - exclusion 
4 Other exclusion 
 If 4, Reason   
                                                                                  If 3 skip “b”, if 1 or 2 skip “c and d” 
b Gender 
1 Male 
2 Female 
3 Other (do not want to disclose, transgender, etc.) 
 
c Name of the person 4  
 
d Initials of the person 4  
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9.5. Person -5 
a Participation 
1 Willing to take part 
2 Type 1 diabetic - exclusion 
3 Gestational diabetes - exclusion 
4 Other exclusion 
 If 4, Reason   
                                                                                  If 3 skip “b”, if 1 or 2 skip “c and d” 
b Gender 
1 Male 
2 Female 
3 Other (do not want to disclose, transgender, etc.) 
 
c Name of the person 5  
 
d Initials of the person 5  
 
9.6. Person - 6 
a Participation 
1 Willing to take part 
2 Type 1 diabetic - exclusion 
3 Gestational diabetes - exclusion 
4 Other exclusion 
 If 4, Reason   
                                                                                  If 3 skip “b”, if 1 or 2 skip “c and d” 
 
b Gender 
1 Male 
2 Female 
3 Other (do not want to disclose, transgender, etc.) 
 
c Name of the person 6  
 
d Initials of the person 6  
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PART 2 – Demographic data and Anthropometric measurements  
Instructions: 
READ CATEGORIES for all questions. CIRCLE ONE 
1 Participant ID:        
 
 
2 Date of Consent:   /   /     
 
 
3 Year of Birth:     
 
                                                                           Note: Choose between 1920 to 1978 
4 Gender: 
1 Male 
2 Female 
3 Other (do not want to disclose, transgender, etc.) 
 
5 Highest level of Education: (Select Education Level) 
1 None 
2 Primary 
3 Secondary 
4 Graduate 
5 Postgraduate or higher 
6 Not classified 
 
6 Occupation: (select occupation) 
1 Not working due to health reasons 
2 Not working due to vision reasons 
3 Housewife 
4 Unemployed 
5 Retired 
6 Unskilled worker 
7 Skilled worker 
8 Professional  
9 Self Employed 
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7 Average Monthly  Individual Income (Rs.)                           
1 Do not want to disclose 
2  
                                                                                    Enter valid Income (0-10000000) 
8 Smoking Status  
1 Non-smoker 
2 Former smoker   
3 Smoker 
                                                                                    If  1 or 2 Go to 9 
8a No of cigarettes per day:  
                                                                                 Please enter valid value (1-99) 
9 Second hand smoke exposure for 
one or more hours per week: 
1 No 
2 Yes 
 
10 
Physical Exercise (Select from 
list) 
1 Sedentary 
2 Mild exercise 
3 Moderate exercise 
4 Vigorous or strenuous exercise 
 
11 
Several periods of stress or 
permanent stress in the last year 
(select Yes or No) 
1 No 
2 Yes 
 
12 
In the last year, was there a time 
when you felt sad, blue or 
depressed for two weeks or more 
in a row (select Yes or No) 
1 No 
2 Yes 
 
13 
Diet: (Select all that applies) 
At least one option should be 
selected. 
1 Salty food or snacks one or more times a day 
2 Deep fried foods or snacks or fast foods 3 or 
more times per week 
3 Eat fruit less than once per day 
4 Eat vegetables less than once per day 
5 Eat meat and / or poultry 2 or more times daily 
6 None of the above 
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14 Diagnosed diabetes Type 2  (Only Type 2 eligible) 
1 Don’t know 
2 No  
3 Yes 
                                                                                 If “Don’t Know or  NO ” Go to 15 
14a 
Duration of diabetes Type 2 
since diagnosis. (enter duration 
in years and 0 – 11 months)  
Years:  Months: 
 
14b Treatment of Diabetes Mellitus: 
1 None / Diet controlled 
2 Oral hypoglycaemic agents only 
3 Insulin only 
4 Both insulin and oral hypoglycaemic agent 
 
14c Complications of diabetes 
mellitus (Select all that applies) 
1 None 
2 Chronic kidney disease 
3 Peripheral neuropathy (diabetic foot) 
4 Diabetic retinopathy 
 
14d Are you aware that diabetes can cause blindness? 
1 No 
2 Yes 
 
15 Cardiovascular disease (Select all that applies) 
1 None 
2 Hypertension 
3 Myocardial infarction 
4 Heart failure 
5 Stroke 
6 Transient ischaemic attack 
 
16 Medical History - any other history 
not covered above 
 
 
17 
Ocular history (Select all that 
applies):  
At least one option should be 
selected 
1 None 
2 Cataract present 
3 Cataract surgery done in at least 1 eye 
4 Glaucoma 
5 AMD (age related macular degeneration) 
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17a 
Other Ocular History - any other 
history not covered before  
 
18 Parental history of diabetes 
1 Both non-diabetic 
2 Either parents diabetic 
3 Both parents diabetic 
 
19 Parental history of heart attack  
1 No 
2 Yes 
 
 20 
Height (cms) 
Enter Valid Height in cms (100-230)  
 
 21 Weight (kgs) Enter valid weight in kgs (30-300)  
 
 22 
Waist circumference (cms) 
Enter valid value in cms (20-300)  
 
 23 Hip circumference (cms) Enter valid value in cms (20-300)  
 
 24 
Systolic Blood pressure (mm Hg) 
Enter valid value (30 - 250) and above 
Diastolic 
 
 
 25 
Diastolic Blood pressure (mm Hg) 
Enter valid value (30 - 250)  
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Part 3- Diabetes Information 
 1 Participant ID:  
 
 2 Diabetes: 
1 No/Don’t know 
2 Yes 
 
 3 
Random Blood sugar (mg/dl):  
Enter valid value (50 - 500) 
 
 
If patient is known diabetic, then whatever the value of RBS, all tests must be carried out. 
If diabetes ‘No / Unknown – RBS < 110 – (End of Survey) 
RBS between 110 and 160 – Answer ‘Carry out all tests ?’ Yes – No 
3a  Carry Out All Tests? 
1 No 
2 Yes 
 
 4 HbA1c (%): 
Enter valid value (4-13)  
 
 5 Microalbuminuria: 
1 No 
2 Yes 
3 Urine sample not available 
 
 6 Total Cholesterol – mg/dL 
Enter Valid value (100-400)  
 
 7 HDL Cholesterol – mg/dL  
Enter Valid value (20-120)  
 
 8 Total Triglycerides – mg/dL 
Enter Valid value (50-500)  
 
 9 LDL Cholesterol – mg/dL  
Enter Valid value (0-450)  
 
 10 Total Cholesterol / HDL Ratio   Enter Valid value (1-33.3)  
 
 11 Non-HDL Cholesterol – mg/dL   Enter Valid value (0-450)  
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 12 Distance Vision in right eye 
(with glasses if available) 
 Select from list 
1 0.0 
2 0.1 
3 0.2 
4 0.3 
5 0.4 
6 0.5 
7 0.6 
8 0.7 
9 0.8 
10 0.9 
11 1.0 
12 1.1 
13 1.2 
14 Worse than or equal to 1.3 
 
 13 Distance Vision in left eye (with 
glasses if available) 
 Select from list 
1 0.0 
2 0.1 
3 0.2 
4 0.3 
5 0.4 
6 0.5 
7 0.6 
8 0.7 
9 0.8 
10 0.9 
11 1.0 
12 1.1 
13 1.2 
14 Worse than or equal to 1.3 
 
 14 
Were the fundus photographs 
taken?                                  
Please enter the Participant ID in 
fundus system 
1 Yes 
2 Not obtainable 
NOTE: If 2 :Please capture the participants front of the eye and upload it in the upload 
page, if the image is not obtainable 
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PART 4 – Eq5d questionnaire 
By placing a tick in one box in each group below, please indicate which statements best describe your 
own health state TODAY 
 
1 Mobility 1 I have no problems in walking about 
2 I have slight problems in walking about 
3 I have moderate problems in walking about 
4 I have severe problems in walking about 
5 I am unable to walk about 
 
2 Self-care 1 I have no problems washing or dressing myself  
2 I have mild problems washing or dressing myself 
3 I have moderate problems washing or dressing 
myself  
4 I have severe problems washing or dressing 
myself 
5 I am unable to wash or dress myself 
 
3 Usual Activities (e.g. work, 
study, housework, family or 
leisure activities) 
1 I have no problems with performing my usual 
activities 
2 I have mild problems with performing my usual 
activities 
3 I have moderate problems with performing my 
usual activities 
4 I have severe problems with performing my usual 
activities 
5 I am unable to perform my usual activities 
 
4 Pain / Discomfort 1 I have no pain or discomfort 
2 I have mild pain or discomfort 
3 I have moderate pain or discomfort 
4 I have severe pain or discomfort 
5 I have extreme pain or discomfort 
 
5 Anxiety / Depression 1 I am not anxious or depressed 
2 I am mildly anxious or depressed 
3 I am moderately anxious or depressed 
4 I am severely anxious or depressed 
5 I am extremely anxious or depressed 
 
6 Vision (using glasses or 
contact lenses if needed) 
1 I have no problems seeing  
2 I have slight problems seeing 
3 I have some problems seeing  
4 I have severe problems seeing 
5 I am unable to see 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039657:e039657. 10 2020;BMJ Open, et al. Sivaprasad S
SMART 
India 
Participant ID:       Participant Initials 
  
Date of Consent:       Year of birth:     
 
13 
 
7 How good or bad your health state, 
is imagined in a scale 0 to 100. The 
best state you can imagine is 
written as 100 and the worst state 
you can imagine is written as 0. 
 
                                                                                Enter value between (0 – 100) 
8 Life satisfaction: All things 
considered, how satisfied are you 
with your life as a whole these 
days in 1 to 10 scale? Please mark 
on the scale where 1 is dissatisfied 
and 10 is satisfied. 
 
                                                                                 Enter value between( 0 – 10) 
 
 
Part 5 - Vision quality of life questionnaire 
1 Does my vision make it likely 
I will injure myself (i.e., when 
moving around the house, 
yard, neighbourhood, or 
workplace)? 
1 It is most unlikely I will injure myself because of my vision 
2 There is a small chance 
3 There is a good chance 
4 It is very likely 
5 Almost certainly my vision will cause me to injure myself 
 
2 Does my vision make it 
difficult to cope with the 
demands in my life? 
 
My vision: 
1 Has no effect on my ability to cope with the demands in my life 
2 Does not make it difficult at all to cope with 
the demands in my life 
3 Makes it a little difficult to cope 
4 Makes it moderately difficult to cope 
5 Makes it very difficult to cope 
6 Makes me unable to cope at all 
 
3 Does my vision affect my 
ability to have friendships? 
 
My vision: 
1 Makes having friendships easier 
2 Has no effect on my friendships 
3 Makes friendships more difficult 
4 Makes friendships a lot more difficult 
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5 Makes friendships extremely difficult 
6 Makes me unable to have friendships 
7 Not applicable; I have no friendships 
 
4 Do I have difficulty organizing 
any assistance I may need? 1 
I have no difficulty organizing any assistance 
I may need 
2 I have a little difficulty organizing assistance 
3 I have moderate difficulty organizing 
assistance 
4 I have a lot of difficulty organizing assistance 
5 I am unable to organize assistance at all 
6 Not applicable; I never need to organize assistance 
 
5 Does my vision make it difficult 
to fulfil the roles I would like to 
fulfil in life (e.g., family roles, 
work roles, community roles)? 
 
My vision: 
1 Has no effect on my ability to fulfil these roles 
2 Does not make it difficult to fulfil these roles 
3 Makes it a little difficult to fulfil these roles 
4 Makes it moderately difficult to fulfil these roles 
5 Makes it very difficult to fulfil these roles 
6 Means I am unable to fulfil these roles 
 
6 Does my vision affect my 
confidence to join in everyday 
activities? 
 
My vision: 
1 Makes me more confident to join in everyday activities 
2 Has no effect on my confidence to join in everyday activities 
3 Makes me feel a little less confident 
4 Makes me feel moderately less confident 
5 Makes me feel a lot less confident 
6 Makes me not confident at all 
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Part 6 - Expense form 
Instructions: Fill the expenses form only for those who are diabetic (if PART 2: 14 = “YES”) 
 
1a Have you seen an eye doctor for diabetic eye disease in the last 3 years? 
1 No 
2 Yes 
                                                                          If ‘No’ skip all question in expense form (skip 1b to 4) 
1b Have you been diagnosed with diabetic eye disease? 
1 No 
2 Yes 
                                                                          If ‘No’ skip to 2a question 
1c 
Have you received any treatment for 
diabetic eye disease in the last one 
year? 
(Select all that applies) 
1 No Treatment 
2 Laser (Macular / PRP) 
3 Injection into the Eye (Anti-VEGF / Steroids) 
4 Surgery (Vitrectomy) 
   At least one option should be selected 
1d How was your vision before treatment? 
1 I had no problems seeing 
2 I had slight problems seeing 
3 I had some problems seeing 
4 I had severe problems seeing 
5 I was unable to see 
    
1e Have you noticed an improvement in your vision following treatment? 
1 No change  
2 Improved 
3 Worsened 
                                                                                              
2a 
What were the total costs in last one 
year for treatment of diabetic eye 
disease (treatment / consultation / 
surgery) 
Rs.  
Enter valid number (>= 0 and less than 999999) 
2b 
If you received any treatment including 
consultations in the last one year 
for diabetic eye disease, was the 
treatment 
1 Free 
2 Concessional Cost 
3 Paid In Full 
 
3 
What were the travel costs for you and 
your carer (family member) in the last 
one year to go to the eye doctors, eye 
hospitals etc. for treatment of diabetic 
eye disease 
Rs.  
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                                                                         Enter valid number (>= 0 and less than 999999) 
 
4 
Did you have to take time off work due 
to diabetic eye disease treatment in the 
last one year? 
1 No 
2 Yes 
 
5a Do you think you have visual impairment? 
1 No 
2 Yes 
5b 
Does your visual impairment affect 
your ability to work? 
1 No 
2 Yes 
 
6 
Did you receive any inpatient treatment 
for kidney disease in the last one year? 
1 No 
2 Yes 
 
7 
Did you receive any inpatient treatment 
for heart condition or stroke 
in the last one year? 
1 No 
2 Yes 
 
8 
Did you receive any treatment for 
diabetic foot disease (Ulcer / Gangrene/ 
Amputation) in the last one year? 
1 No 
2 Yes 
 
9 a 
What were the costs in last one year for treatment of diabetes or its complications 
(heart conditions, kidney problems, feet problems etc) other than diabetic eye disease 
Break Up Medications Rs. 
Investigations Rs. 
Consultations Rs. 
Hospitalization Rs. 
Sum Rs. 
Or 
Total Rs. 
 
9 b 
If you received any treatment in the last 
one year for diabetes or its complications 
(heart conditions, kidney problems, feet 
problems etc), was the treatment… 
1 Free 
2 Concessional Cost 
3 Pain In Full 
 
 
10 
What were the travel costs for you and 
your carer (family member) in the last one 
year to go to the doctors, hospitals etc for 
treatment of diabetes or its complications 
(exclude diabetic eye disease costs) 
Rs.  
Enter valid number (>= 0 and less than 999999) 
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11 
Did you have to take time off work due to 
diabetes or its complications treatment 
(other than diabetic eye disease) in the last 
one year? 
1 No 
2 Yes 
 
 
PART 7 - Fundus Image  
Instruction: 
Please enter the Participant ID in fundus system. Capture Macula centered and Disc centered 
images and upload minimum 4 images of good quality to the database. 
Please capture the participant's front of the eye and upload it in the upload page, if the image 
is not obtainable. 
Please write the Fundus cam image ID if unable to transfer the image to database  
Image No 
Image ID 
OD OS 
1   
2   
3   
4   
5   
6   
7   
8   
 
 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-039657:e039657. 10 2020;BMJ Open, et al. Sivaprasad S
